Clinical trials have now begun – with the goal of unleashing cancer-killing white blood cells to attack the tumour.

Clinical trials have now begun – with the goal of unleashing cancer-killing white blood cells to attack the tumour.

The cancer hijacks white blood cells called B-cells and manipulates them to make CD38.

Research suggests it then deprives other cancer-killing white blood cells of the energy they need to attack the tumour.

The cancer hijacks white blood cells called B-cells and manipulates them to make CD38.

Given to 24 men with advanced prostate cancer, isatuximab – an immunotherapy used to treat blood cancer – re-energised the cancer-killing white blood cells, a conference heard last month.